Adamas Pharmaceuticals (ADMS) (ADMS) had five minutes on Thursday night to feel good about its first U.S. drug approval before sniping over pricing kicked in.
The FDA approved the new Adamas product, to be marketed under the brand name Gocovri, to reduce dyskinesia (involuntary movements) experienced by some Parkinson’s disease patients on levodopa therapy. Adamas noted Thursday that Gocovri is the first and only FDA-approved medicine for this indication, but the claim comes with an asterisk.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
The answer is no it should not. I wonder if it is possible to take the original in divided doses?